Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases

Published by	Decision Resources, Inc.
Published	August, 2009	Product code	98547
Content info	28 Pages
Price	US $ 4600 PDF by E-mail (Global License)

Introduction
Related Reports

Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases published by Decision Resources, Inc. in August, 2009. This report consists of 28 Pages and the price starts from US $ 4600.

Introduction

Abstract

Introduction

Despite the robust drug market for immune and infl ammatory diseases and their high prevalence, diagnostics associated with these diseases do not constitute a large marketplace. Although researchers are working to discover biomarkers, associate genes with disease, and develop diagnostics, a healthy commercial market for diagnostic technologies and biomarker-based products in immune and infl ammatory therapeutic areas is still years away. The present opportunity is to identify biomarkers with high levels of sensitivity and specificity that can be validated for use in drug or diagnostic development and, particularly, in disease management to guide and target the use of therapies.

Get the Answers You Need to Shape Your Strategy

Current ability to diagnose immune/infl ammatory diseases accurately and quickly is limited. What are the common diagnostic approaches? Which indications exhibit the highest level of unmet need in terms of diagnostics? How can diagnostics/biomarker developers tap the opportunities that current shortcomings present?
Biomarkers do not currently play a large role in clinical practice, but their potential utility is apparent. What do thought leaders say about biomarkers for immune/infl ammatory diseases? How can biomarkers target and track therapies? What developments of note are under way?
Large companies are interested in using biomarkers or diagnostics developed by smaller companies to target patients who are candidates for their immune/infl ammatory pipeline drugs. What proportion of the companies involved in these deals are private/venture-backed companies, small-cap companies, or academic institutions? How many of the 52 companies we analyze relied on backing from large-cap pharmaceutical companies?

Scope

Indications: systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), asthma, chronic obstructive pulmonary disease (COPD), and the infl ammatory bowel diseases (IBDs) Crohn' s disease (CD) and ulcerative colitis (UC).
Diagnosis rates: diagnosed prevalence of select immune/infl ammatory diseases based on Decision Resources' epidemiology.
Current and future approaches: indication-specific modalities, challenges, opportunities, identified and posited biomarkers, published research results.
Dealmaking: Select deals for diagnostics and biomarkers, indication focus of dealmaking, classifications of dealmaking companies.

Mentioned in This Report

Companies

Advanced Proteome Therapeutics
Aldo-Union
Amgen
Apieron
Apitope International
Atreus Pharmaceuticals
Auguron
Axis-Shield
Biogen Idec
Biologix Diagnostics
Bio-Rad
Biovitrum
BL&H
Bristol-Myers Squibb
Celera
Cellatope
Centocor
Chugai
Colonix Medical
Compugen
Cypress Bioscience
Gene Network Sciences
GeneNews
Genentech
GlaxoSmithKline
Immunodiagnostic Systems
Mitsubishi Tanabe
MorphoSys
Nordic Bioscience Diagnostics
Pfizer
Phadia
Pharmaxis
Praxis Pharmaceutical
Procognia
Proteomika
Pulmocor
Roche
Sanofi-Aventis
Schering-Plough
SensiGen
Sequenom
Source MDx
WaferGen
Wireless bioDevices
XDx
Zenyaku Kogyo

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Introduction
Untapped Opportunity for Immune and Infl ammatory Biomarkers
Diagnosing and Monitoring Immune and Infl ammatory Diseases
- Arthritic Conditions
  - Rheumatoid Arthritis
  - Juvenile Idiopathic Arthritis
  - Ankylosing Spondylitis
- Systemic Lupus Erythematosus
- Pulmonary and Respiratory Conditions
  - Asthma
  - Chronic Obstructive Pulmonary Disease
- Infl ammatory Bowel Disease
  - Crohn' s Disease
  - Ulcerative Colitis
Industry Trailblazers Advancing Biomarker Research and Product Development
- Musculoskeletal Immune/Infl ammatory Biomarker/Diagnostic Deals
- General Immune/Infl ammatory Biomarker/Diagnostic Deals
- Respiratory Immune/Infl ammatory Biomarker/Diagnostic Deals
Strategic Considerations
- Major Breakthroughs Are Needed
- Consider the Value of Initiatives to Increase Awareness and Physician Education
- Ability to Predict Response to Therapy Would Be a Game Changer

Tables

1. Immune and Infl ammatory Diseases Covered in This Report and Select Associated Biomarkers
2. Lupus Foundation of America' s Top Ten Advances for Systemic Lupus Erythematosus in 2008
3. Potential Biomarkers of Asthma and Chronic Obstructive Pulmonary Disease
4. Select Companies Focusing on Advancing Biomarker Opportunities in Immune and Infl ammatory Diseases

Figures

1. Overall and Diagnosed Prevalence of Select Immune and Infl ammatory Diseases in the United States, 2008
2. Pathological Changes in the Joints of Patients with Rheumatoid Arthritis
3. Rheumatologist-Estimated Percentage of Ankylosing Spondylitis Patients with Common Ankylosing Spondylitis Symptoms
4. Comorbidities Associated with COPD
5. Percentage of Immune/Infl ammatory Biomarker/Diagnostic Deals by Deal Focus
6. Percentage of Immune/Infl ammatory Biomarker/Diagnostic Deals by Therapeutic Area
7. Percentage of Companies Involved in Immune/Infl ammatory Biomarker/Diagnostic Deals by Company Type